PDGene


	The Michael J. Fox Foundation for Parkinson's Research

		Research
		News & Events
		Funding Programs
		About

	PD Online Research

	Alzheimer Research Forum

		Current Papers
		ARF Recommends
		Research News

Gene overview of all published PD-association studies for DRD3

Gene:

DRD3 (D3DR; ETM1; FET1)

View on AlzGene View on SZGene

Protein:

dopamine receptor D3 (essential tremor 1)

Chromosome:

3 (View: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y MT)

Status:

Updated 29 June 2010

1. Case-Control Studies (by ethnic group)
				PD Cases				Normal Controls
Study	Population	Source	# Polys	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result	Comment
Caucasian
Fung, 2006	Overlaps with Simon-Sanchez, 2009 (USA)	CL	3 (detail)	267 (-)	C	-	-	270 (-)	68 (55-88)	n.a.	Submit comment
Pankratz, 2008	USA (PROGENI, GenePD)	CL	3 (detail)	857 (41%)	C	61.9 + 10.8 (-)	-	867 (60%)	54.8 + 13.1 (-)	Negative	Submit comment
Simon-Sanchez, 2009	USA, Germany (GWAS)	CL,PO	3 (detail)	1745 (45%)	C	55.8 (7-98)	-	4047 (50%)	-	Negative
Asian
Higuchi, 1995	Japan	CL	1 (detail)	70 (-)	C	-	67.1 + 9.8 (-)	70 (-)	67.1 + 10 (-)	Negative	Submit comment
Lee, 2009	Korea	CL	1 (detail)	404 (50%)	C	54 (-)	63.1 (-)	559 (54%)	58.4 + 10.6 (37-85)	Negative
Mizuta, 2006	Overlaps with Mizuta, 2008	CL	2 (detail)	882 (56%)	C	57.4 + 10.9 (-)	64.9 + 9.8 (-)	938 (48%)	45.3 + 16.3 (-)	n.a.	Submit comment
Mizuta, 2008	Japan	CL	2 (detail)	882 (56%)	C	57.4 + 10.9 (-)	64.9 + 9.8 (-)	938 (48%)	45.6 + 16.3 (-)	Negative	Submit comment
Momose, 2002	Japan	CL	1 (detail)	232 (51%)	C	54.1 + 10.5 (24-80)	-	249 (49%)	-	Negative	Submit comment
Nanko, 1993	Japan	CL	1 (detail)	60 (-)	C	-	-	90 (-)	-	Negative	Submit comment
Nanko, 1994	Overlaps with Nanko, 1993	CL	1 (detail)	71 (49%)	C	-	64.9 + 9.7 (40-84)	90 (48%)	27.8 + 6.4 (19-54)	n.a.	Submit comment
Toda, 2003	Overlaps with Momose, 2002	CL	1 (detail)	232 (51%)	C	54.1 + 10.5 (24-80)	-	249 (49%)	-	n.a.	Submit comment
Wang, 2001	China	CL	2 (detail)	140 (39%)	C	56.8 + 10.8 (30-83)	66.9 + 11.2 (34-86)	140 (-)	-	Negative	Submit comment
Other/Mixed
Juyal, 2006	India (South)	CL	5 (detail)	147 (35%)	C	-	47.7 + 13.8 (-)	130 (35%)	58.2 + 12.3 (-)	Trend	Submit comment
Juyal, 2006	India (North)	CL	5 (detail)	340 (29%)	C	-	50.6 + 11.9 (20-78)	344 (28%)	57.3 + 9.9 (-)	Positive	Submit comment
Keeling 2009	USA	CL	1 (detail)	448 (46%)	C	61.8 + 12.5 (5-85)	72.2 + 10.9 (-)	428 (-)	-	Negative

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

2. Family-Based Studies (by ethnic group)
				Affecteds				Unaffecteds
Study	Population	# Polys	# Families	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result	Comment
Caucasian
Maraganore, 2005	USA	1 (detail)	443	443 (39%)	C	61 (31-94)	68 (33-96)	443 (52%)	66 (29-90)	Negative	Submit comment

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine PD diagnosis -> "C" (clinical PD diagnosis), "N" (neuropathological PD diagnosis), "M" (mixed, i.e. PD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.